David Green, the president of Harvard Bioscience, takes it personally when the company’s stock price takes a swan dive, like it did in May after the company announced disappointing first-quarter results.

He said that plunge cost him $10 million.

But, tell him that loss is only on paper, and the look you get will convince you of the pain he has incurred.

Green and Chane Graiziano acquired HBIO in 1996 and took it public in 2000, and today still hold some 18 percent of company stock.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.